| 5.20 Data as of 2:10pm ET |  0.00 / 0.00%Today’s Change | 4.71 Today|||52-Week Range 6.80 | +0.19% Year-to-Date |
| SECTOR Health Services | INDUSTRY Services to the Health Industry | MARKET CAP $486.2M |
Company Description
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. Its drug candidates also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. The company was founded on November 30, 1995 and is headquartered in Carmiel, Israel.
Employees
Shareholders
| Other institutional | 9.33% |
| Mutual fund holders | 25.93% |
| Individual stakeholders | 15.70% |
Top Executives
| David Aviezer, PhD, MBA | President, Chief Executive Officer & Director |
| Tzvi Palash | Chief Operating Officer |
| Yossi Maimon, MBA, CPA | CFO, Secretary, Treasurer, VP & Accounting Officer |
| Raul Chertkoff, MD, MBA | Vice President-Medical Affairs |
| Yoseph Shaaltiel, PhD | Director, EVP-Research & Development |
.
